GlassScriptPhysician profile
Amber Mansoor
NPI 1588076343
$5,681.24
in general payments reported to CMS, 2019-2025
23 companies · $2,011 in 2025
The $2,011 reported for 2025 was more than what 94% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.78 · 2020: $64.77 · 2021: $350 · 2022: $534 · 2023: $1,328 · 2024: $1,315 · 2025: $2,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,649 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,648.76 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $883.66 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $570.26 | 2022-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $530.15 | 2023-2025 | Spravato |
| Axsome Therapeutics, INC. | $483.24 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $402.09 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $402.09 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $396.52 | 2019-2025 | Rexulti |
| Corium, LLC | $351.42 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $190.14 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $185.12 | 2024-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $182.02 | 2024-2025 | Fanapt |
| Abbott Laboratories | $175.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $164.50 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $150.31 | 2020-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.81 | 2024-2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Farxiga |
| Amgen INC. | $122.07 | 2023 | Tavneos |
| Noven Therapeutics, LLC | $63.02 | 2024-2025 | Secuado, Xelstrym |
| Vertical Pharmaceuticals, LLC | $55.44 | 2024-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $50.43 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $35.02 | 2022-2023 | Cotempla Xr-Odt |
| Tris Pharma INC | $16.67 | 2022 | |
| Shire North American Group INC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Mansoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.